Skip to main content
Erschienen in: Supportive Care in Cancer 11/2016

29.06.2016 | Original Article

Symptoms and quality of life in patients with brain metastases receiving whole-brain radiation therapy

verfasst von: Erin Wong, Liying Zhang, Leigha Rowbottom, Nicholas Chiu, Leonard Chiu, Rachel McDonald, May Tsao, Elizabeth Barnes, Cyril Danjoux, Edward Chow

Erschienen in: Supportive Care in Cancer | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Patients with multiple brain metastases may be treated with whole-brain radiation therapy (WBRT). For these patients, symptom palliation and improvement of quality of life (QOL) and performance status is of the upmost importance. The objective of the present study was to determine the symptom experience and overall QOL in patients with brain metastases before and after WBRT.

Methods

A total of 14 symptom scores and overall QOL were collected prospectively in 217 patients for up to 3 months. Wilcoxon signed rank test was applied to determine significant symptoms and QOL changes. Spearman’s correlations were applied to determine the relationship between symptom scores and QOL.

Results

Appetite loss, weakness, and nausea significantly increased from baseline, while balance, headache, and anxiety significantly decreased from baseline. At baseline, all symptoms other than coordination were significantly correlated with QOL. At 1-month follow-up (FU), changes in concentration, weakness, coordination, and balance were significantly associated with QOL changes. At 2-month FU, changes in pain, insomnia, concentration, balance, and depression were significantly associated with QOL changes. At 3-month FU, only change in nausea was significantly associated with QOL changes.

Conclusions

Following WBRT, certain symptoms may influence overall QOL to a greater extent than others, which may fluctuate with time.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Gavrilovic IT, Posner JB (2005) Brain metastases: epidemiology and pathophysiology. J Neuro-Oncol 75(1):5–14CrossRef Gavrilovic IT, Posner JB (2005) Brain metastases: epidemiology and pathophysiology. J Neuro-Oncol 75(1):5–14CrossRef
2.
Zurück zum Zitat Thomas SS, Dunbar EM (2010) Modern multidisciplinary management of brain metastases. Curr Oncol Rep 12(1):34–40CrossRefPubMed Thomas SS, Dunbar EM (2010) Modern multidisciplinary management of brain metastases. Curr Oncol Rep 12(1):34–40CrossRefPubMed
3.
Zurück zum Zitat Gori S, Rimondini S, De Angelis V, Colozza M, Bisagni G, Moretti G, et al. (2007) Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oncologist 12(7):766–773CrossRefPubMed Gori S, Rimondini S, De Angelis V, Colozza M, Bisagni G, Moretti G, et al. (2007) Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oncologist 12(7):766–773CrossRefPubMed
4.
Zurück zum Zitat Bezjak A, Adam J, Barton R, Panzarella T, Laperriere N, Wong CS, et al. (2002) Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer 38(4):487–496CrossRefPubMed Bezjak A, Adam J, Barton R, Panzarella T, Laperriere N, Wong CS, et al. (2002) Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer 38(4):487–496CrossRefPubMed
5.
Zurück zum Zitat Tsao MN, Rades D, Wirth A, Lo SS, Danielson BL, Gaspar LE, et al. (2012) Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 2(3):210–225CrossRefPubMedPubMedCentral Tsao MN, Rades D, Wirth A, Lo SS, Danielson BL, Gaspar LE, et al. (2012) Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 2(3):210–225CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Pulenzas N, Khan L, Tsao M, Zhang L, Lechner B, Thavarajah N, et al. (2014) Fatigue scores in patients with brain metastases receiving whole brain radiotherapy. Support Care Cancer 22(7):1757–1763CrossRefPubMed Pulenzas N, Khan L, Tsao M, Zhang L, Lechner B, Thavarajah N, et al. (2014) Fatigue scores in patients with brain metastases receiving whole brain radiotherapy. Support Care Cancer 22(7):1757–1763CrossRefPubMed
7.
Zurück zum Zitat Tsao MN, Lloyd N, Wong RK, Chow E, Rakovitch E, Laperriere N, et al. (2012) Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev 4:CD003869PubMed Tsao MN, Lloyd N, Wong RK, Chow E, Rakovitch E, Laperriere N, et al. (2012) Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev 4:CD003869PubMed
8.
9.
Zurück zum Zitat Popovic M, Nguyen J, Chen E, Di Giovanni J, Zeng L, Chow E (2012) Comparison of the EORTC QLQ-BM22 and the FACT-BP for assessment of quality of life in cancer patients with bone metastases. Expert Rev Pharmacoecon Outcomes Res 12(2):213–219CrossRefPubMed Popovic M, Nguyen J, Chen E, Di Giovanni J, Zeng L, Chow E (2012) Comparison of the EORTC QLQ-BM22 and the FACT-BP for assessment of quality of life in cancer patients with bone metastases. Expert Rev Pharmacoecon Outcomes Res 12(2):213–219CrossRefPubMed
10.
Zurück zum Zitat Caissie A, Nguyen CE, Zhang L, Saghal A, Clemons M, et al. (2012) Quality of life in patients with brain metastases using the EORTC QLQ-BN20 + 2 and QLQ-C15-PAL. Int J Radiat Oncol Biol Phys 83(4):1238–1245CrossRefPubMed Caissie A, Nguyen CE, Zhang L, Saghal A, Clemons M, et al. (2012) Quality of life in patients with brain metastases using the EORTC QLQ-BN20 + 2 and QLQ-C15-PAL. Int J Radiat Oncol Biol Phys 83(4):1238–1245CrossRefPubMed
11.
Zurück zum Zitat Chiu L, Chiu N, Zeng L, Zhang L, Popovic M, Chow R, et al. (2012) Quality of life in patients with primary and metastatic brain cancer as reported in the literature using the EORTC QLQ-BN20 and QLQ-C30. Expert Rev Pharmacoecon Outcomes Res 12(6):831–837CrossRefPubMed Chiu L, Chiu N, Zeng L, Zhang L, Popovic M, Chow R, et al. (2012) Quality of life in patients with primary and metastatic brain cancer as reported in the literature using the EORTC QLQ-BN20 and QLQ-C30. Expert Rev Pharmacoecon Outcomes Res 12(6):831–837CrossRefPubMed
12.
Zurück zum Zitat Hall WA, Djalilian HR, Nussbaum ES, Cho KH (2000) Long-term survival with metastatic cancer to the brain. Med Oncol 17(4):279–286CrossRefPubMed Hall WA, Djalilian HR, Nussbaum ES, Cho KH (2000) Long-term survival with metastatic cancer to the brain. Med Oncol 17(4):279–286CrossRefPubMed
13.
Zurück zum Zitat Wong J, Hird A, Kirouâ E, Mauro A, Napolskikh J, Chow E (2008) Quality of life in brain metastases radiation trials: a literature review. Curr Oncol 15(5):25–45CrossRefPubMedPubMedCentral Wong J, Hird A, Kirouâ E, Mauro A, Napolskikh J, Chow E (2008) Quality of life in brain metastases radiation trials: a literature review. Curr Oncol 15(5):25–45CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Chow E, Davis L, Holden L, Tsao M, Danjoux C (2005) Prospective assessment of patient-rated symptoms following whole brain radiotherapy for brain metastases. J Pain Symptom Manag 30(1):18–23CrossRef Chow E, Davis L, Holden L, Tsao M, Danjoux C (2005) Prospective assessment of patient-rated symptoms following whole brain radiotherapy for brain metastases. J Pain Symptom Manag 30(1):18–23CrossRef
15.
Zurück zum Zitat Yaneva MP, Semerdjieva MA (2006) Assessment of the effect of palliative radiotherapy for cancer patients with intracranial metastases using EORTC-QOL-C30 questionnaire. Folia Med (Plovdiv) 48(2):23–29 Yaneva MP, Semerdjieva MA (2006) Assessment of the effect of palliative radiotherapy for cancer patients with intracranial metastases using EORTC-QOL-C30 questionnaire. Folia Med (Plovdiv) 48(2):23–29
16.
Zurück zum Zitat Gerrard GE, Prestwich RJ, Edwards A, Russon LJ, Richards F, Johnston CF, et al. (2003) Investigating the palliative efficacy of whole-brain radiotherapy for patients with multiple-brain metastases and poor prognostic features. Clin Oncol (R Coll Radiol) 15(7):422–428CrossRef Gerrard GE, Prestwich RJ, Edwards A, Russon LJ, Richards F, Johnston CF, et al. (2003) Investigating the palliative efficacy of whole-brain radiotherapy for patients with multiple-brain metastases and poor prognostic features. Clin Oncol (R Coll Radiol) 15(7):422–428CrossRef
17.
Zurück zum Zitat Addeo R, Caraglia M, Faiola V, Capasso E, Vincenzi B, Montella L, et al. (2007) Concomitant treatment of brain metastasis with whole brain radiotherapy and temozolomide is active and improves quality of life. BMC Cancer 7:18CrossRefPubMedPubMedCentral Addeo R, Caraglia M, Faiola V, Capasso E, Vincenzi B, Montella L, et al. (2007) Concomitant treatment of brain metastasis with whole brain radiotherapy and temozolomide is active and improves quality of life. BMC Cancer 7:18CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Scott C, Suh J, Stea B, Nabid A, Hackman J (2007) Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole-brain radiation therapy for brain metastases. Am J Clin Oncol 30(6):580–587CrossRefPubMed Scott C, Suh J, Stea B, Nabid A, Hackman J (2007) Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole-brain radiation therapy for brain metastases. Am J Clin Oncol 30(6):580–587CrossRefPubMed
Metadaten
Titel
Symptoms and quality of life in patients with brain metastases receiving whole-brain radiation therapy
verfasst von
Erin Wong
Liying Zhang
Leigha Rowbottom
Nicholas Chiu
Leonard Chiu
Rachel McDonald
May Tsao
Elizabeth Barnes
Cyril Danjoux
Edward Chow
Publikationsdatum
29.06.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 11/2016
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3326-8

Weitere Artikel der Ausgabe 11/2016

Supportive Care in Cancer 11/2016 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.